Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present its transformation and growth strategy at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022, at 4:20 p.m. EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present its transformation and growth strategy at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022, at 4:20 p.m. EDT. The presentation will be accessible via a live audio webcast on Myriad's investor information webpage. Myriad is recognized for developing genetic tests that assess disease risk and guide treatment, significantly enhancing patient care while reducing healthcare costs. It was named among the World’s Most Innovative Companies for 2022 by Fast Company.
Details
News Market Reaction – MYGN
The recorded move for MYGN in the trading session of this news was -2.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, June 09, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation and growth plan during a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Monday, June 13, 2022 at 4:20 p.m. EDT.
The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and commercializes genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.
| Media Contact: | Investor Contact: |
| Megan Manzari | Nathan Smith |
| (385) 318-3718 | (801) 505-5067 |
| Megan.Manzari@myriad.com | Nathan.Smith@myriad.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.